Company Overview and News

 
SAIL’s strategic approach to improve operational profitability helps margins

2018-09-21 freepressjournal.in
Addressing the shareholders of Steel Authority of India Ltd. (SAIL) on Company’s 46th Annual General Meeting, Chairman and Managing Director, SAIL, Saraswati Prasad said the persistent strategic approach to improve operational profitability assisted SAIL to improve the EBIDTA. ‘
SAIL

 
Loss-making SAIL declines dividend to government for FY18

2018-09-01 freepressjournal.in
New Delhi : State-run steel maker SAIL has informed the government that it is not in a position to pay dividend for 2017-18 as it suffered a loss of Rs 281 crore in the fiscal, an official said.
SAIL

 
An evening walk down Dalal Street | Sensex fails to hold 38,000, Nifty posts record close

2018-08-17 moneycontrol
The market ended a truncated week on a good note, as benchmark indices closed with strong gains. The Nifty ended the day at a record closing high, while the Sensex ended higher by almost 300 points. Having said that, it failed to hold 38,000-mark.
HINDALCO SAUKF 533262 VEDL SAUA AKLD HNDNF SAUD SAIL 500470 RAMKY TTST TATASTEEL TATLY IONEXCHANG 500113 500477 500214 ASTRAZEN 506820 AKLS 500440 ASHOKLEY

 
SAIL supplies 60,000 tonnes steel for railway project in Manipur

2018-06-19 freepressjournal.in
New Delhi: State-run SAIL today said it has supplied 60,000 tonnes steel for 111 km long Jiribam-Imphal broad gauge railway project in Manipur.
SAIL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to NSE:SAIL / STEEL AUTHORITY OF INDIA LTD. on message board site Silicon Investor.

SeaEscape (SEPI). Setting Sail for Profits. SeaEscape (SEPI). Setting Sail for Profits. SeaEscape (SEPI). Setting Sail for Profits. BOAT - Revenge Marine Boat Manufacturer Sailing Proud BOAT - Revenge Marine Boat Manufacturer Sailing Proud BOAT - Revenge Marine Boat Manufacturer Sailing Proud
SAILORS, BOATERS AND PARROTHEADS UNITE!!! SAILORS, BOATERS AND PARROTHEADS UNITE!!! SAILORS, BOATERS AND PARROTHEADS UNITE!!!